Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
By How Much Is The Cytokine Release Syndrome Management Market Expected To Expand Between 2025 And 2029?
The cytokine release syndrome management market size has experienced strong growth in recent years. It is projected to expand from $22.32 billion in 2024 to $23.76 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.5%. The expansion witnessed in the historic period can be ascribed to escalating healthcare expenditure, enhanced awareness, evolving lifestyles, increased disposable income, the adoption of personalized medicine approaches, and the growing application of targeted therapies.
The cytokine release syndrome management market is projected to experience robust expansion in the coming years. This market is set to reach $30.48 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.4%. The anticipated growth during this period stems from several factors, including the increasing demand for diagnostic tools and treatments, augmented government funding, a greater need for effective therapies, an expanding geriatric population, and an uptick in initiatives from both public and private entities. Key developments shaping the market in the forecast timeframe encompass minimally invasive breast biopsy devices, various strategic partnerships and collaborations, the provision of home-based antibiotic infusion services, the introduction of novel drug delivery systems, and the incorporation of electronic health records for more efficient infection tracking.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24199&type=smp
Which Drivers Are Supporting Growth Of The Cytokine Release Syndrome Management Market?
The expanding application of targeted therapies is projected to fuel the expansion of the cytokine release syndrome management market in the future. These therapies involve medications or interventions specifically engineered to impede cancer’s proliferation and dissemination by disrupting molecular targets implicated in tumor formation. The growing adoption of targeted therapies stems mainly from their capacity to accurately home in on cancerous cells, thereby minimizing harm to healthy ones, boosting treatment effectiveness, and lessening adverse reactions in contrast to conventional treatments. Effective management of cytokine release syndrome is crucial for optimizing targeted therapies, as it controls severe inflammatory responses, thereby improving the safety and efficacy of treatments like CAR-T cell therapy and immune checkpoint inhibitors. As an illustration, data from the American Society of Gene and Cell Therapy, a US-based organization, indicated in January 2024 that the fourth quarter of 2023 saw a 10% rise in the number of gene therapies undergoing Phase III clinical trials, representing the first such quarterly increase since the third quarter of 2022. Consequently, the expanding utilization of targeted therapies is propelling the growth of the cytokine release syndrome management market.
What Are The Major Segment Categories Driving The Cytokine Release Syndrome Management Market Growth?
The cytokine release syndrome managementmarket covered in this report is segmented –
1) By Treatment Type: Monoclonal Antibodies; Corticosteroids; Intravenous Immunoglobulin (IVIG); Targeted Therapy; Supportive Care; Other Treatment Types
2) By Indication: Chimeric Antigen Receptor (CAR) T-Cell Therapy; Immune Checkpoint Inhibitors; Hematopoietic Stem Cell Transplantation (HSCT); Autoimmune Diseases; Infections; Other Indications
3) By Route Of Administration: Intravenous (IV); Subcutaneous (SC); Oral; Intramuscular (IM); Intrathecal; Other Routes Of Administration
4) By End Users: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Clinics; Research Institutions; Other End Users
Subsegments:
1) By Monoclonal Antibodies: Tocilizumab; Siltuximab; Infliximab; Rituximab; Other Monoclonal Antibodies
2) By Corticosteroids: Dexamethasone; Prednisone; Methylprednisolone; Hydrocortisone; Other Corticosteroids
3) By Intravenous Immunoglobulin (IVIG): Immunoglobulin G (IgG)-Based Intravenous Immunoglobulin; Immunoglobulin A (IgA)-Based Intravenous Immunoglobulin; Immunoglobulin M (IgM)-Based Intravenous Immunoglobulin; Polyvalent Intravenous Immunoglobulin; Other Types of Intravenous Immunoglobulin
4) By Targeted Therapy: Janus Kinase (JAK) Inhibitors; Interleukin-6 (IL-6) Inhibitors; Tumor Necrosis Factor-Alpha (TNF-a) Inhibitors; Bruton’s Tyrosine Kinase (BTK) Inhibitors; Other Targeted Agents
5) By Supportive Care: Antipyretic Medications; Analgesic Medications; Intravenous Fluids And Electrolyte Solutions; Oxygen Therapy; Vasopressor Agents
6) By Other Treatment Types: Plasmapheresis (Therapeutic Plasma Exchange); Antihistamine Medications; Leukapheresis; Experimental Therapies; Nutritional Support
Which Competitive Trends Are Defining The Cytokine Release Syndrome Management Market Structure?
Major companies operating in the cytokine release syndrome management market are prioritizing clinical trials to develop innovative therapies, including host-directed small molecule drugs. These treatments are intended to modulate the immune response and lessen the severity of cytokine storms without compromising the body’s capacity to fight infections or cancer. A host-directed small molecule drug is defined as a low molecular weight compound that targets the host’s immune signaling pathways to suppress excessive cytokine production, thereby assisting in the management of cytokine release syndrome (CRS) by preventing immune system overactivation. For instance, in April 2025, CytoAgents Inc., a US-based biotechnology company, reported the successful conclusion of the first dose-escalation cohort in its Phase 1b/2a clinical trial of CTO1681, a host-directed small molecule drug designed to prevent and treat CRS in patients undergoing CAR T-cell therapy. This investigational therapy demonstrated a favorable safety profile, showing no dose-limiting toxicities or interference with CAR T-cell efficacy. The trial, employing a rolling six dose-escalation design, is currently evaluating the safety, tolerability, and preliminary efficacy of CTO1681, in addition to determining the recommended phase 2 dose.
Who Are The Top Performing Companies In The Cytokine Release Syndrome Management Market In Recent Years?
Major companies operating in the cytokine release syndrome management market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Incyte Corporation, Swedish Orphan Biovitrum AB, Biocon Limited, MacroGenics Inc., Legend Biotech Corporation, Bluebird Bio Inc., InflaRx N.V., Humanigen Inc.
Download The Full Report For Exclusive Market Findings:
How Do Regional Market Performances Compare Within The Cytokine Release Syndrome Management Industry?
North America was the largest region in the cytokine release syndrome management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cytokine release syndrome management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Cytokine Release Syndrome Management Market Report:
https://www.thebusinessresearchcompany.com/customise?id=24199&type=smp
Browse Through More Reports Similar to the Global Cytokine Release Syndrome Management Market 2025, By The Business Research Company
Hepatorenal Syndrome Treatment Global Market Report 2025
Myelodysplastic Syndrome Drugs Global Market Report 2025
Dry Eye Syndrome Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/dry-eye-syndrome-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model